SCHEDULE: IMMUNIC, INC. - 683 Capital Management Exit Filing

683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman have filed an exit report indicating they no longer beneficially own more than five percent of IMMUNIC, INC.'s common stock.

Summary

• This filing is an amendment to a Schedule 13G, specifically an exit filing, by 683 Capital Management, LLC, 683 Capital Partners, LP, and Ari Zweiman.
• The reporting persons state that they no longer beneficially own more than five percent of the outstanding shares of IMMUNIC, INC. (the Issuer).
• As of May 15, 2026, the reporting persons collectively beneficially owned 474,200 shares of Common Stock, representing approximately 3.4% of the outstanding shares.
• This ownership includes 245,000 shares of Common Stock and warrants to purchase an additional 229,200 shares of Common Stock, which are currently exercisable.
• The percentage is calculated based on 13,621,526 shares of Common Stock outstanding as of April 28, 2026, plus the shares issuable upon exercise of the warrants.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing as having a negative sentiment due to it being an 'exit filing,' indicating a reduction in significant ownership, which can signal a lack of confidence or a strategic shift away from the company.

Positives

• The reporting persons have reduced their stake below the 5% threshold, indicating a potential shift in their investment strategy or a realization of gains.
• The filing confirms that the reporting persons no longer hold a significant enough stake to be considered a major beneficial owner, which could reduce immediate selling pressure if they were to divest further.

Negatives

• The reduction in ownership below 5% suggests a decrease in the reporting persons' confidence or strategic interest in IMMUNIC, INC.
• The fact that this is an 'exit filing' implies a complete divestment or a significant reduction from a previously larger holding, which could be interpreted negatively by the market.

Risks

• The filing does not explicitly mention any risks. However, the act of exiting a significant ownership position could imply perceived risks or a lack of future growth potential by the reporting persons.

Future Outlook

The filing is an exit filing, indicating that the reporting persons no longer hold a significant stake. Therefore, it does not contain forward-looking statements or guidance from the company regarding its future outlook.

Management Comments

• This Amendment No. 2 constitutes an exit filing for the Reporting Persons (as defined below), as the Reporting Persons no longer beneficially own more than five percent of the outstanding shares of the Issuer.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by institutional investors and indicate ownership stakes. An 'exit filing' specifically signals that the reporting entity no longer meets the threshold for significant beneficial ownership, often implying a strategic decision to reduce or eliminate their position in the company.

Stakeholder Impact

• Shareholders: The reduction in a significant investor's stake might be perceived negatively, potentially impacting short-term share price sentiment. However, it also means less immediate selling pressure from this entity.
• Management: The company's management may interpret this as a signal of reduced confidence from a former significant investor.
• Creditors: No direct impact is indicated as the filing relates to equity ownership.

Next Steps

• The reporting persons have completed their exit from holding a significant beneficial ownership stake in IMMUNIC, INC.

Key Dates

Recommendation

This filing is an exit report from a significant investor, indicating they no longer hold a substantial stake. While this can be a negative signal, it does not provide direct information about the company's operational performance or future prospects. Therefore, a 'hold' recommendation is appropriate, suggesting investors should await further company-specific news or performance updates before making a decisive move.

Keywords

IMMUNIC, INC., Schedule 13G, Exit Filing, Beneficial Ownership, 683 Capital Management, 683 Capital Partners, Ari Zweiman, Common Stock, Warrants, SEC Filing